Literature DB >> 3898489

Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients.

M S Kennedy, G C Yee, T R Mcguire, T M Leonard, J J Crowley, H J Deeg.   

Abstract

We retrospectively analyzed the relationship of serum cyclosporine concentration to renal dysfunction in 63 marrow transplant recipients who received cyclosporine for prophylaxis of acute graft-versus-host disease. Patients were divided into three groups according to their mean trough cyclosporine concentration for the first 28 days of therapy: less than 150, 150-250, and greater than 250 ng/ml. Baseline renal function and exposure to nephrotoxic antibiotics was comparable in the three groups. Renal dysfunction was defined as doubling of baseline serum creatinine. The likelihood of developing renal dysfunction was analyzed with Kaplan-Meier product limit estimates. The log-rank test was used to compare the three groups. Fifty-four (86%) of the patients developed renal dysfunction. The incidence of renal dysfunction was 73%, 95%, and 100%, and it developed at a median of 46, 29, and 20 days in patients with a mean trough concentration of less than 150, 150-250, and greater than 250 ng/ml, respectively (P less than 0.001). Eight of the nine patients who did not develop renal dysfunction had a mean trough concentration of less than 150 ng/ml. These data indicate that the incidence and the rate of development of renal dysfunction are related to serum cyclosporine concentration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898489     DOI: 10.1097/00007890-198509000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

Authors:  A Lindholm; R Dahlqvist; G G Groth; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 4.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 5.  Prevention and management of graft-versus-host disease. Practical recommendations.

Authors:  G B Vogelsang; L E Morris
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 6.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 8.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

9.  Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  K B Miller; D P Schenkein; R Comenzo; J K Erban; T Fogaren; C A Hirsch; E Berkman; A Rabson
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

10.  Postmortem examination of the kidney in allogeneic hematopoietic stem cell transplantation recipients: possible involvement of graft-versus-host disease.

Authors:  Eiji Kusumi; Masahiro Kami; Shigeo Hara; Junichi Hoshino; Yutaka Yamaguchi; Naoko Murashige; Yukiko Kishi; Yugo Shibagaki; Taro Shibata; Tomoko Matsumura; Koichiro Yuji; Kazuhiro Masuoka; Atsushi Wake; Shigesaburo Miyakoshi; Shuichi Taniguchi
Journal:  Int J Hematol       Date:  2008-02-09       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.